Radium-223 Use in Clinical Practice and Variables Associated With Completion of Therapy

Rana R. McKay, Susanna Jacobus, Matthew Fiorillo, Elisa M. Ledet, Patrick M. Cotogna, Allie E. Steinberger, Heather A. Jacene, Oliver Sartor, Mary Ellen Taplin

Research output: Contribution to journalArticle

Abstract

Background: Radium-223 has shown clinical efficacy in metastatic castration-resistant prostate cancer. Despite improvement in quality of life and survival, practice patterns and utility of this agent outside the context of clinical trials have not been fully characterized. The primary objective in this study was to evaluate variables associated with completion of 5 to 6 radium-223 doses. Patients and Methods: We conducted retrospective analyses of patients who received radium-223 (n = 135). Patients were classified into 3 cohorts: 1 to 2, 3 to 4, or 5 to 6 radium-223 doses. We evaluated the association of clinical and laboratory variables with the number of cycles administered (5-6 vs. 1-4 doses). Results: Twenty-five patients (18.5%) received 1 to 2 radium-223 doses, 27 (20.0%) received 3 to 4, and 83 (61.5%) received 5 to 6. The most common reasons for treatment discontinuation included disease progression (61.5%, n = 40), patient preference (15.4%, n = 10), and toxicity (10.8%, n = 7). Factors associated with therapy completion in univariate analysis included previous sipuleucel-T treatment (P = .068), no previous abiraterone or enzalutamide treatment (P = .007), hemoglobin ≥ lower limit of normal (LLN; . P = .006), white blood cell count ≥ LLN (P = .045), absolute neutrophil count (ANC) ≥ LLN (P = .049), lower alkaline phosphatase (P = .029), and lower lactate dehydrogenase levels (P = .014). Factors associated with therapy completion in multivariable analysis included previous sipuleucel-T treatment (P = .009), hemoglobin ≥ LLN (P = .037), and ANC ≥ LLN (P = .029). Conclusion: Several clinical parameters are associated with radium-223 therapy completion. In general, these parameters reflect earlier disease stage. These data are hypothesis-generating and prospective testing of the optimal number of radium-223 doses is warranted.

Original languageEnglish (US)
JournalClinical Genitourinary Cancer
DOIs
StateAccepted/In press - Jul 6 2016
Externally publishedYes

Fingerprint

Radium
Therapeutics
Neutrophils
Patient Preference
Castration
Leukocyte Count
L-Lactate Dehydrogenase
Alkaline Phosphatase
Disease Progression
Prostatic Neoplasms
Hemoglobins
Quality of Life
Clinical Trials
Survival

Keywords

  • Bone metastases
  • Castration resistance
  • Dosing
  • Prostate cancer
  • Radiopharmaceutical

ASJC Scopus subject areas

  • Oncology
  • Urology

Cite this

McKay, R. R., Jacobus, S., Fiorillo, M., Ledet, E. M., Cotogna, P. M., Steinberger, A. E., ... Taplin, M. E. (Accepted/In press). Radium-223 Use in Clinical Practice and Variables Associated With Completion of Therapy. Clinical Genitourinary Cancer. https://doi.org/10.1016/j.clgc.2016.08.015

Radium-223 Use in Clinical Practice and Variables Associated With Completion of Therapy. / McKay, Rana R.; Jacobus, Susanna; Fiorillo, Matthew; Ledet, Elisa M.; Cotogna, Patrick M.; Steinberger, Allie E.; Jacene, Heather A.; Sartor, Oliver; Taplin, Mary Ellen.

In: Clinical Genitourinary Cancer, 06.07.2016.

Research output: Contribution to journalArticle

McKay, RR, Jacobus, S, Fiorillo, M, Ledet, EM, Cotogna, PM, Steinberger, AE, Jacene, HA, Sartor, O & Taplin, ME 2016, 'Radium-223 Use in Clinical Practice and Variables Associated With Completion of Therapy', Clinical Genitourinary Cancer. https://doi.org/10.1016/j.clgc.2016.08.015
McKay, Rana R. ; Jacobus, Susanna ; Fiorillo, Matthew ; Ledet, Elisa M. ; Cotogna, Patrick M. ; Steinberger, Allie E. ; Jacene, Heather A. ; Sartor, Oliver ; Taplin, Mary Ellen. / Radium-223 Use in Clinical Practice and Variables Associated With Completion of Therapy. In: Clinical Genitourinary Cancer. 2016.
@article{636723f7264e45dbb89e93e1e11bf2d8,
title = "Radium-223 Use in Clinical Practice and Variables Associated With Completion of Therapy",
abstract = "Background: Radium-223 has shown clinical efficacy in metastatic castration-resistant prostate cancer. Despite improvement in quality of life and survival, practice patterns and utility of this agent outside the context of clinical trials have not been fully characterized. The primary objective in this study was to evaluate variables associated with completion of 5 to 6 radium-223 doses. Patients and Methods: We conducted retrospective analyses of patients who received radium-223 (n = 135). Patients were classified into 3 cohorts: 1 to 2, 3 to 4, or 5 to 6 radium-223 doses. We evaluated the association of clinical and laboratory variables with the number of cycles administered (5-6 vs. 1-4 doses). Results: Twenty-five patients (18.5{\%}) received 1 to 2 radium-223 doses, 27 (20.0{\%}) received 3 to 4, and 83 (61.5{\%}) received 5 to 6. The most common reasons for treatment discontinuation included disease progression (61.5{\%}, n = 40), patient preference (15.4{\%}, n = 10), and toxicity (10.8{\%}, n = 7). Factors associated with therapy completion in univariate analysis included previous sipuleucel-T treatment (P = .068), no previous abiraterone or enzalutamide treatment (P = .007), hemoglobin ≥ lower limit of normal (LLN; . P = .006), white blood cell count ≥ LLN (P = .045), absolute neutrophil count (ANC) ≥ LLN (P = .049), lower alkaline phosphatase (P = .029), and lower lactate dehydrogenase levels (P = .014). Factors associated with therapy completion in multivariable analysis included previous sipuleucel-T treatment (P = .009), hemoglobin ≥ LLN (P = .037), and ANC ≥ LLN (P = .029). Conclusion: Several clinical parameters are associated with radium-223 therapy completion. In general, these parameters reflect earlier disease stage. These data are hypothesis-generating and prospective testing of the optimal number of radium-223 doses is warranted.",
keywords = "Bone metastases, Castration resistance, Dosing, Prostate cancer, Radiopharmaceutical",
author = "McKay, {Rana R.} and Susanna Jacobus and Matthew Fiorillo and Ledet, {Elisa M.} and Cotogna, {Patrick M.} and Steinberger, {Allie E.} and Jacene, {Heather A.} and Oliver Sartor and Taplin, {Mary Ellen}",
year = "2016",
month = "7",
day = "6",
doi = "10.1016/j.clgc.2016.08.015",
language = "English (US)",
journal = "Clinical Genitourinary Cancer",
issn = "1558-7673",
publisher = "Elsevier",

}

TY - JOUR

T1 - Radium-223 Use in Clinical Practice and Variables Associated With Completion of Therapy

AU - McKay, Rana R.

AU - Jacobus, Susanna

AU - Fiorillo, Matthew

AU - Ledet, Elisa M.

AU - Cotogna, Patrick M.

AU - Steinberger, Allie E.

AU - Jacene, Heather A.

AU - Sartor, Oliver

AU - Taplin, Mary Ellen

PY - 2016/7/6

Y1 - 2016/7/6

N2 - Background: Radium-223 has shown clinical efficacy in metastatic castration-resistant prostate cancer. Despite improvement in quality of life and survival, practice patterns and utility of this agent outside the context of clinical trials have not been fully characterized. The primary objective in this study was to evaluate variables associated with completion of 5 to 6 radium-223 doses. Patients and Methods: We conducted retrospective analyses of patients who received radium-223 (n = 135). Patients were classified into 3 cohorts: 1 to 2, 3 to 4, or 5 to 6 radium-223 doses. We evaluated the association of clinical and laboratory variables with the number of cycles administered (5-6 vs. 1-4 doses). Results: Twenty-five patients (18.5%) received 1 to 2 radium-223 doses, 27 (20.0%) received 3 to 4, and 83 (61.5%) received 5 to 6. The most common reasons for treatment discontinuation included disease progression (61.5%, n = 40), patient preference (15.4%, n = 10), and toxicity (10.8%, n = 7). Factors associated with therapy completion in univariate analysis included previous sipuleucel-T treatment (P = .068), no previous abiraterone or enzalutamide treatment (P = .007), hemoglobin ≥ lower limit of normal (LLN; . P = .006), white blood cell count ≥ LLN (P = .045), absolute neutrophil count (ANC) ≥ LLN (P = .049), lower alkaline phosphatase (P = .029), and lower lactate dehydrogenase levels (P = .014). Factors associated with therapy completion in multivariable analysis included previous sipuleucel-T treatment (P = .009), hemoglobin ≥ LLN (P = .037), and ANC ≥ LLN (P = .029). Conclusion: Several clinical parameters are associated with radium-223 therapy completion. In general, these parameters reflect earlier disease stage. These data are hypothesis-generating and prospective testing of the optimal number of radium-223 doses is warranted.

AB - Background: Radium-223 has shown clinical efficacy in metastatic castration-resistant prostate cancer. Despite improvement in quality of life and survival, practice patterns and utility of this agent outside the context of clinical trials have not been fully characterized. The primary objective in this study was to evaluate variables associated with completion of 5 to 6 radium-223 doses. Patients and Methods: We conducted retrospective analyses of patients who received radium-223 (n = 135). Patients were classified into 3 cohorts: 1 to 2, 3 to 4, or 5 to 6 radium-223 doses. We evaluated the association of clinical and laboratory variables with the number of cycles administered (5-6 vs. 1-4 doses). Results: Twenty-five patients (18.5%) received 1 to 2 radium-223 doses, 27 (20.0%) received 3 to 4, and 83 (61.5%) received 5 to 6. The most common reasons for treatment discontinuation included disease progression (61.5%, n = 40), patient preference (15.4%, n = 10), and toxicity (10.8%, n = 7). Factors associated with therapy completion in univariate analysis included previous sipuleucel-T treatment (P = .068), no previous abiraterone or enzalutamide treatment (P = .007), hemoglobin ≥ lower limit of normal (LLN; . P = .006), white blood cell count ≥ LLN (P = .045), absolute neutrophil count (ANC) ≥ LLN (P = .049), lower alkaline phosphatase (P = .029), and lower lactate dehydrogenase levels (P = .014). Factors associated with therapy completion in multivariable analysis included previous sipuleucel-T treatment (P = .009), hemoglobin ≥ LLN (P = .037), and ANC ≥ LLN (P = .029). Conclusion: Several clinical parameters are associated with radium-223 therapy completion. In general, these parameters reflect earlier disease stage. These data are hypothesis-generating and prospective testing of the optimal number of radium-223 doses is warranted.

KW - Bone metastases

KW - Castration resistance

KW - Dosing

KW - Prostate cancer

KW - Radiopharmaceutical

UR - http://www.scopus.com/inward/record.url?scp=84994718045&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84994718045&partnerID=8YFLogxK

U2 - 10.1016/j.clgc.2016.08.015

DO - 10.1016/j.clgc.2016.08.015

M3 - Article

JO - Clinical Genitourinary Cancer

JF - Clinical Genitourinary Cancer

SN - 1558-7673

ER -